1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
41 citations
,
November 1993 in “Journal of The American Academy of Dermatology” DPCP helps treat severe hair loss, but 5% minoxidil doesn't add benefits.
Combining systemic steroids and dithranol can effectively regrow hair in severe alopecia areata.
January 2024 in “Case Reports in Endocrinology” Cortisone tapering may help improve severe myasthenia gravis and alopecia areata after thymectomy.
December 2025 in “Current Issues in Molecular Biology” New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.
February 2020 in “Zagazig University Medical Journal” The treatment is effective for mild alopecia areata but often causes mild side effects.
23 citations
,
March 2019 in “Environmental Chemistry Letters” Cyclodextrins improve how steroid drugs work and are used in marketed medications and environmental applications.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
12 citations
,
June 2010 in “Journal of dermatology” Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
February 2024 in “Deleted Journal” Cabergoline effectively treated a dog's hyperadrenocorticism.
33 citations
,
January 2009 in “Contraception” Chlormadinone acetate is a strong, well-tolerated hormone used in birth control and hormone therapy with benefits for menstrual pain and skin conditions.
March 2024 in “International journal of pharmaceutics. X” Spanlastic-laden nanogel could be a better way to deliver hair growth medication through the skin for treating hair loss.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
January 2014 in “대한피부과학회지” A hepatitis B patient lost hair in patches after starting and stopping a treatment with pegylated interferon alpha2a.
97 citations
,
November 1986 in “Journal of Steroid Biochemistry” Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.
8 citations
,
January 2018 in “Journal of the American Academy of Dermatology” Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.
18 citations
,
November 2009 in “Archives of Dermatology” Calcipotriol doesn't prevent hypertrophic scars, but keratinocyte activation is important in scar formation.
The C-CAT tool helps assess and improve treatment for central centrifugal cicatricial alopecia.
April 2002 in “Postgraduate medicine” A 4-year-old boy's itchy, scaly scalp and hair loss were correctly diagnosed as tinea capitis after initial misdiagnosis.
March 2018 in “Gazi medical journal” Adults with Beta Thalassemia Major are more likely to have skin, hair, and nail disorders.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
60 citations
,
September 2001 in “British journal of dermatology/British journal of dermatology, Supplement” Topical contact sensitizers can treat certain skin conditions by changing the immune response.